Sierra Oncology, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SRRA research report →
Price Chart
About the company
Sierra Oncology, Inc. is a biopharmaceutical firm focused on the late-stage research, development, and commercialization of therapeutic solutions for patients with blood disorders and various cancers. The company's primary drug candidate is momelotinib, an orally administered, selective inhibitor that targets Janus kinase 1 (JAK1), JAK2, and Activin A receptor type 1 (ACVR1).
- CEO
- Nicholas Glover
- IPO
- 2015
- Employees
- 109
- HQ
- Vancouver, BC, CA
Get TickerSpark's AI analysis on SRRA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $0
- P/E
- -7.70
- PEG
- 0.43
- P/S
- 0.00
- P/B
- 7.59
- EV/EBITDA
- 1.10
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -97.61%
- ROIC
- -97.74%
Latest fiscal year · YoY change
- Revenue
- $0-100.0%
- Gross Profit
- $0-100.0%
- Op Income
- $-94,662,000
- Net Income
- $-94,659,000-17.0%
- EPS
- $-7.14+7.3%
- OCF Growth
- -50.8%
- FCF Growth
- -50.9%
- 52W High
- $55.19
- 52W Low
- $14.91
- 50D MA
- $54.73
- 200D MA
- $33.69
- Beta
- 0.02
- RSI (14)
- 78
- Avg Volume
- 651.46K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Sierra Oncology ended 2019 with a much stronger cash position and reiterated that 2020 is focused on enrolling MOMENTUM, the pivotal Phase 3 trial intended to support momelotinib registration.· March 3, 2020
- MOMENTUM is the company’s near-term focus, with topline data expected in Q4 2021 and a targeted U.S. filing in Q2 2022.
- Management believes momelotinib is differentiated because it aims to address the three hallmarks of myelofibrosis: anemia, symptoms, and spleen size.
- The company said it completed a financing in January 2020 and ended 2019 with $137.5 million in cash and cash equivalents.
- Sierra plans multiple data disclosures in 2020 from SIMPLIFY-1 and SIMPLIFY-2 to further support momelotinib’s durability, safety, and anemia benefits.
- Management framed the market opportunity around patients with anemia and thrombocytopenia, both in first-line and second-line myelofibrosis settings.
For 2019, cash used in operating activities was $51.2 million. Operating expenses were approximately $67 million versus $55.4 million in 2018, and GAAP net loss was $88.3 million versus $53.3 million a year earlier. Non-GAAP adjusted net loss was $51.2 million versus $36.5 million. The company said 2019 included a $10.5 million non-cash R&D charge and a $20.9 million charge tied to warrant liabilities. In the fourth quarter, Sierra raised $103 million of gross proceeds in an equity offering, netting $97.7 million, repaid its $5 million term loan, and ended the year with $137.5 million in cash and cash equivalents versus $106 million at December 31, 2018. Management said current resources should fund development into the second half of 2022, and if Series B warrants are fully exercised the company could receive about $34 million more. No formal revenue or EPS figures were reported on the call.
Nick Glover positioned momelotinib as Sierra’s central strategic asset and said the company is focused on regulatory and commercial success. He emphasized that the drug could matter across the full myelofibrosis spectrum, especially for anemic and thrombocytopenic patients who are poorly served by current options. His tone was confident and promotional, but tied closely to the clinical data package and the company’s plan to use the totality of SIMPLIFY-1, SIMPLIFY-2, and MOMENTUM in a future filing.
Sukhi Jagpal highlighted the 2019 financial results and the improved balance sheet. He cited $51.2 million of cash used in operating activities, about $67 million of operating expenses, GAAP net loss of $88.3 million, and non-GAAP adjusted net loss of $51.2 million; he also noted the $10.5 million non-cash R&D charge and a $20.9 million warrant-liability-related charge. On the financing side, he said the company raised $103 million gross in Q4 2019, ended the year with $137.5 million in cash and cash equivalents, and expects that cash to carry the business into the second half of 2022, before any additional warrant proceeds.
Analysts focused on MOMENTUM execution, including site activations, enrollment pace, and whether the study could reach 180 patients by mid-2021. Management declined to give a site-by-site update but said the trial is on track, with countries clearing and sites activating, and pointed investors to ClinicalTrials.gov as a lagging indicator. Questions also centered on the long-term access study and whether more data would come from it; management said 120 patients were still on study at the last update and that the dataset will support publications on durability and safety. Another line of questioning addressed danazol as comparator and whether the study design is strong enough; management said danazol is largely an anemia agent with little effect on spleen or symptoms, and that the crossover and 2:1 randomization were designed to maximize the chance of success.
The bull case from this call is that Sierra now has enough cash and a clearer development path to keep momelotinib moving toward registration. Management repeatedly stressed a differentiated profile in anemia, transfusion burden, symptoms, and spleen, plus a large existing clinical dataset of more than 820 treated patients and long-term responders. They also said the company expects multiple data readouts in 2020 to reinforce durability and safety, which could broaden awareness before the MOMENTUM result.
The main risk is execution: MOMENTUM still has to enroll 180 patients, and topline data are not expected until Q4 2021. Management also acknowledged that danazol is a relatively weak comparator and that they must rely on site activation, enrollment cadence, and the overall trial design to reach their timelines. More broadly, all of the value discussion depends on successful regulatory approval, and management said that without approval the asset has little or no value.
AI summary of the company's earnings call · Paraphrased · Not investment advice
of shares held by institutions
110 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Parametric Portfolio Associates LLC | 43.72K | ▲ 43.72K |
| Frazier Management LLC | 20.32K | ▼ 34.34K |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 1, 22 | Vivo Opportunity, LLC | sell | 75,749 |
| Jul 1, 22 | Vivo Opportunity, LLC | sell | 431,947 |
| Jul 1, 22 | ORBIMED ADVISORS LLC | sell | 170,437 |
| Jul 1, 22 | ORBIMED ADVISORS LLC | sell | 226,704 |
| Jul 1, 22 | Ashiya Mona | sell | 170,437 |
| Jul 1, 22 | Ashiya Mona | sell | 1,500 |
| Jul 1, 22 | Ashiya Mona | sell | 6,000 |
| Jul 1, 22 | Ashiya Mona | sell | 6,874 |
| Jul 1, 22 | Ashiya Mona | sell | 226,704 |
| Jul 1, 22 | Aggarwal Gaurav | sell | 2,735,853 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our SRRA coverage
Recent articles, reports, and earnings notes.
No research on SRRA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SRRA report →GSK Receives Regulatory Nod for Consumer Healthcare Demerger
zacks.com · Jun 2
SIERRA ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sierra Oncology, Inc - SRRA
businesswire.com · May 5
SIERRA ONCOLOGY INVESTOR ALERT - Kuznicki Law PLLC Investigates Proposed Sale of Sierra Oncology, Inc - SRRA
businesswire.com · May 2
Best Biotech Stocks To Buy Now? 5 To Know
stockmarket.com · Apr 14
SHAREHOLDER ALERT: Weiss Law Investigates Sierra Oncology, Inc.
prnewswire.com · Apr 13
Late-Stage Biopharmaceutical Sierra Oncology announces acquisition by GSK
invezz.com · Apr 13
Why Is Sierra Oncology (SRRA) Stock Up Today?
investorplace.com · Apr 13
Sierra Oncology Stock Is Soaring: Here's Why
benzinga.com · Apr 13
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.